Cardiovascular Disease

ADHD Meds & Cardiovascular Disease

A meta-analysis of nearly 4M participants found no association between the use of medications to treat ADHD and any cardiovascular disease outcome. 

ADHD medications are known to increase heart rate and blood pressure, and as the use of ADHD medication increases in both adults and children, there has been understandable concern that ADHD meds may lead to adverse cardiovascular effects. 

But these findings suggest these medications may actually be safe for the heart. 

In the systematic review and meta-analysis, researchers analyzed 19 studies from the US, Spain, Denmark, Hong Kong, Canada, and South Korea, involving 3.9M children, adolescents, and adults. 

Researchers found no statistically significant association between ADHD and any CVD outcome among…

  • Children and adolescents (pooled adjusted relative risk: 1.18)
  • Young or middle-aged adults (RR: 1.04)
  • Older adults (RR: 1.59)

Both stimulants and non-stimulants showed no association. When the authors looked at specific cardiovascular outcomes (such as cardiac arrest, arrhythmias, cerebrovascular diseases, or myocardial infarction) there was still no association. There was even no association among those with preexisting CVD.  

The Takeaway

Overall, the findings are reassuring and suggest these medications — which have raised concerns about CVD risk — may be safe for the heart. While the authors acknowledge that a “modest risk increase could not be ruled out,” the findings should comfort readers with cardiovascular patients being treated for ADHD.

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Cardiology August 28, 2025

Cardiologists, Practice What You Preach! August 28, 2025

Cardiologists might be struggling with the same lifestyle challenges they counsel patients about, as a national survey of ACC members revealed significant gaps between what physicians’ recommend and how they act. The ACC CardioSurve study surveyed 166 U.S. cardiologists about their training in lifestyle medicine and clinical recommendations across all six lifestyle pillars, revealing some […]

Obesity Care August 25, 2025

GLP-1s Work, But Not for Free August 25, 2025

Real-world semaglutide (Wegovy) patients might be experiencing a healthcare cost paradox, after a recent analysis in JAMA showed that GLP-1s successfully reduce weight and improve cardiovascular risk factors, but lead to increased patient healthcare expenditures in the short term. The real-world analysis examined 23.5k adults prescribed semaglutide between January 2018 and January 2025 across two […]

Electrophysiology August 21, 2025

Conduction-System Pacing Succeeds at Treating AV Block August 21, 2025

Conduction-system pacing could be poised to reshape standard care for atrioventricular (AV) block patients after the randomized CSPACE trial demonstrated its significant benefits over traditional right ventricular septal pacing. Taking a closer look at CSP’s potential, the CSPACE trial enrolled 202 patients with AV block at two Australian hospitals, randomizing them to conduction-system pacing or […]

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!